Sasaki's MLB debut this season has been a rollercoaster, flashing elite strikeout capability coupled with control issues. He went 1-1 in his eight starts, pitching 34.1 innings with 24 strikeouts ...

Sasaki's return is not the only reason for the Dodgers to celebrate, as they are also about to welcome back a key piece in Blake Treinen, a veteran whose dominant arm, when healthy, is vital for ...

Roki Sasaki, one of the jewels of Japanese pitching and a star signing for the Los Angeles Dodgers, remains on hold due to a right shoulder injury. It is a sensitive blow because, ...

Los Angeles Dodgers rookie phenom Roki Sasaki has been on the injured list since early May with a right shoulder impingement , and manager Dave Roberts is providing a more positive update on ...

Prior to landing on the IL, Sasaki sported a 4.72 ERA with 24 strikeouts and 1.485 WHIP across 34.1 innings pitched. The right-hander recorded an ERA+ of 85, well below the league average for ...

Biotech ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations By Nick Paul Taylor Jul 1, 2025 9:38am Oncternal Therapeutics solid tumor CAR-T Cell & Gene Therapy ...

Tomra Systems: Solid Double-Digit RoR, Still A Slim Buy Jun. 30, 2025 3:45 PM ET Tomra Systems ASA (TMRAY) Stock, TMRAF Stock TMRAY, TMRAF Wolf Report Investing Group ...

View the latest Rotork PLC (ROR) stock price, news, historical charts, analyst ratings and financial information from WSJ.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...